Table 1 Updates in WHO/ICC classifications of AML

AML with defining genetic abnormalities**

APL with PML::RARA fusion

APL with t (15;17) (q24.1;q21.2)/PML::RARA^§

APL with other RARA rearrangements^§

AML with RUNX1::RUNX1T1 fusion

AML with t (8;21) (q22;q22.1)/RUNX1::RUNX1T1^§

AML with CBFB::MYH11 fusion

AML with inv (16) (p13.1q22) or t (16;16) (p13.1;q22)/CBFB::MYH11^§

AML with DEK::NUP214 fusion

AML with t (6;9) (p22.3;q34.1)/DEK::NUP214^§

AML with RBM15::MRTFA fusion

Not recognized

AML with BCR::ABL1 fusion

AML with t (9;22) (q34.1;q11.2)/BCR::ABL1^#

AML with KMT2A rearrangement

AML with t (9;11) (p21.3;q23.3)/MLLT3::KMT2A^§

AML with other KMT2A rearrangements^§

AML with MECOM rearrangement

AML with inv (3) (q21.3q26.2) or t (3;3) (q21.3;q26.2)/GATA2; MECOM (EVI1)^§

AML with other MECOM rearrangements^§

AML with NUP98 rearrangement

Not recognized

AML with NPM1 mutation

AML with mutated NPM1^§

AML with CEBPA mutation

AML with in-frame bZIP CEBPA mutations^§

AML, myelodysplasia-related^†

AML^# and MDS/AML^§ with mutated TP53

AML^# and MDS/AML^§ with myelodysplasia-related gene mutations

AML^# and MDS/AML^§ with myelodysplasia-related cytogenetic abnormalities

MDS/AML NOS^§

AML with other defined genetic alterations

AML with other rare recurring translocations^#

Myeloid proliferations associated with Down syndrome

AML, defined by differentiation

AML with minimal differentiation

AML NOS^#

AML without maturation

AML with maturation

Acute basophilic leukemia

Acute myelomonocytic leukemia

Acute monocytic leukemia

Acute erythroid leukemia

Acute megakaryoblastic leukemia

Myeloid sarcoma

Myeloid sarcoma

Blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm